Intensity Therapeutics Common Stock Performance
| INTS Stock | 0.42 0.01 2.33% |
Intensity Therapeutics holds a performance score of 7 on a scale of zero to a hundred. The company retains a Market Volatility (i.e., Beta) of -0.0822, which attests to not very significant fluctuations relative to the market. As returns on the market increase, returns on owning Intensity Therapeutics are expected to decrease at a much lower rate. During the bear market, Intensity Therapeutics is likely to outperform the market. Use Intensity Therapeutics Common downside variance, as well as the relationship between the daily balance of power and period momentum indicator , to analyze future returns on Intensity Therapeutics Common.
Risk-Adjusted Performance
Fair
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Intensity Therapeutics Common are ranked lower than 7 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively unfluctuating basic indicators, Intensity Therapeutics unveiled solid returns over the last few months and may actually be approaching a breakup point. ...more
Last Split Factor 2:1 | Last Split Date 1996-04-08 |
1 | Connecticut Biotech Firm Intensity Therapeutics Navigates Critical Reverse Stock Split - FinancialContent | 10/24/2025 |
2 | Nasdaq Surges Over 1 Apple Earnings Top Views | 10/31/2025 |
3 | Intensity Therapeutics GAAP EPS of -0.06 in-line | 11/07/2025 |
4 | Intensity Therapeutics Granted 180-Day Extension to Regain Compliance with Nasdaqs Minimum Bid Price Requirement | 12/05/2025 |
5 | Acquisition by Talamo Joseph of 14482 shares of Intensity Therapeutics at 0.262 subject to Rule 16b-3 | 12/31/2025 |
6 | Why Intensity Therapeutics Inc. stock is rated strong buy - Lightweight Speed Options trail grip notes for mixed terrain - ulpravda.ru | 01/09/2026 |
| Begin Period Cash Flow | 8.6 M | |
| Total Cashflows From Investing Activities | 6.4 M | |
| Free Cash Flow | -15.2 M |
Intensity | Build AI portfolio with Intensity Stock |
Intensity Therapeutics Relative Risk vs. Return Landscape
If you would invest 30.00 in Intensity Therapeutics Common on October 13, 2025 and sell it today you would earn a total of 12.00 from holding Intensity Therapeutics Common or generate 40.0% return on investment over 90 days. Intensity Therapeutics Common is currently generating 4.7313% in daily expected returns and assumes 50.127% risk (volatility on return distribution) over the 90 days horizon. In different words, most equities are less risky than Intensity, and most traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Intensity Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Intensity Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Intensity Therapeutics Common, and traders can use it to determine the average amount a Intensity Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0944
| High Returns | Best Equity | INTS | ||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Based on monthly moving average Intensity Therapeutics is performing at about 7% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Intensity Therapeutics by adding it to a well-diversified portfolio.
Intensity Therapeutics Fundamentals Growth
Intensity Stock prices reflect investors' perceptions of the future prospects and financial health of Intensity Therapeutics, and Intensity Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Intensity Stock performance.
| Return On Equity | -2.35 | ||||
| Return On Asset | -1.02 | ||||
| Current Valuation | 18.01 M | ||||
| Shares Outstanding | 60.06 M | ||||
| Price To Book | 3.46 X | ||||
| EBITDA | (16.27 M) | ||||
| Net Income | (16.27 M) | ||||
| Total Debt | 138 K | ||||
| Book Value Per Share | 0.15 X | ||||
| Cash Flow From Operations | (15.22 M) | ||||
| Earnings Per Share | (0.55) X | ||||
| Market Capitalization | 24.96 M | ||||
| Total Asset | 4.78 M | ||||
| Retained Earnings | (66.78 M) | ||||
| Working Capital | 1.61 M | ||||
About Intensity Therapeutics Performance
Assessing Intensity Therapeutics' fundamental ratios provides investors with valuable insights into Intensity Therapeutics' financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Intensity Therapeutics is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 53.87 | 47.88 | |
| Return On Tangible Assets | (3.91) | (4.11) | |
| Return On Capital Employed | (6.30) | (5.98) | |
| Return On Assets | (3.91) | (4.11) | |
| Return On Equity | (6.41) | (6.09) |
Things to note about Intensity Therapeutics performance evaluation
Checking the ongoing alerts about Intensity Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Intensity Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Intensity Therapeutics is way too risky over 90 days horizon | |
| Intensity Therapeutics has some characteristics of a very speculative penny stock | |
| Intensity Therapeutics appears to be risky and price may revert if volatility continues | |
| Net Loss for the year was (16.27 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Intensity Therapeutics generates negative cash flow from operations | |
| Latest headline from prnewswire.com: BOLD MAGAZINE LAUNCHES AS JACKSONVILLES NEW CULTURAL AUTHORITY -- WHERE BUSINESS, CULTURE THE FUTURE COLLIDE |
- Analyzing Intensity Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Intensity Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Intensity Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Intensity Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Intensity Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Intensity Therapeutics' stock. These opinions can provide insight into Intensity Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Intensity Stock Analysis
When running Intensity Therapeutics' price analysis, check to measure Intensity Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Intensity Therapeutics is operating at the current time. Most of Intensity Therapeutics' value examination focuses on studying past and present price action to predict the probability of Intensity Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Intensity Therapeutics' price. Additionally, you may evaluate how the addition of Intensity Therapeutics to your portfolios can decrease your overall portfolio volatility.